Gihong Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gihong Park has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hyunsoo Chung
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea
3 shared publications - Bokyung Kim
Department of Internal Medicine, Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Korea
2 shared publications - Bongseong Kim
Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea
1 shared publication - Ji Kon Ryu
Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital Seoul National University College of Medicine Seoul Republic of Korea
1 shared publication - Kyungdo Han
Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea
1 shared publication - Sang Gyun Kim
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea
1 shared publication
Latest Publications
- Open Access
- 17 September 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (3) , 397-406
Association between Type 2 Diabetes and Gastrointestinal Bleeding: A Nationwide Population-Based Cohort Study in South Korea
Gihong Park, Bongseong Kim, Kyungdo Han, Hyunsoo Chung. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250109
- 17 September 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (3) , 397-406
Open AccessAssociation between Type 2 Diabetes and Gastrointestinal Bleeding: A Nationwide Population-Based Cohort Study in South Korea
Gihong Park, Bongseong Kim, Kyungdo Han, Hyunsoo Chung. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250109
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gastric Cancer
- Vol. 25 (3) , 497-508
A Novel Digital Method for Accurate Endoscopic Size Measurement of Gastric Lesions: A Comparative Study With Visual and Forceps-Assisted Estimation
Yun S, et al. J Gastric Cancer. 2025 Jul;25:e37. https://doi.org/10.5230/jgc.2025.25.e37
- 1 January 2025
- Published by XMLink in Journal of Gastric Cancer
- Vol. 25 (3) , 497-508
Open AccessA Novel Digital Method for Accurate Endoscopic Size Measurement of Gastric Lesions: A Comparative Study With Visual and Forceps-Assisted Estimation
Yun S, et al. J Gastric Cancer. 2025 Jul;25:e37. https://doi.org/10.5230/jgc.2025.25.e37
- Open Access
- 10 December 2023
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 23 (4) , 268-276
Types of 23S Ribosomal RNA Point Mutations Affecting Helicobacter pylori Eradication Rates in Clarithromycin-Based Triple Therapy
Objectives: The A2142G and A2143G mutations in the 23S ribosomal ribonucleic acid (rRNA) of Helicobacter pylori are the most common mutations associated with clarithromycin resistance. This study aimed to determine the differences in H. pylori eradication rates in patients infected with bacteria carrying the A2142G and A2143G mutations who were treated with clarithromycin-based triple therapy. Methods: Data from a previous randomized controlled trial were analyzed retrospectively. Eradication rates were compared based on the presence of H. pylori carrying the A2142G and A2143G mutations. A meta-analysis was also conducted of relevant studies containing data regarding patients who received clarithromycin-based therapy due to infections with H. pylori harboring 23S rRNA mutations. Results: No significant difference was observed in H. pylori eradication rates between patients infected with wild-type bacteria (95.7% [44/46]) compared with those infected with bacteria carrying the A2142G mutation (100.0% [3/3]; p>0.9). However, the eradication rate was significantly lower for patients infected with bacteria carrying the A2143G mutation (16.7% [1/6]; p<0.001) than for those infected with wild-type bacteria or bacteria with the A2142G mutation (100.0% [3/3]; p=0.048). In the meta-analysis, the between-group comparisons yielded similar results. Although patients infected with bacteria having the A2142G mutation exhibited no significant risk difference (RD) for eradication compared with those infected with wild-type bacteria (RD=-0.05 [-0.18 to 0.08]; I2=0%; p=0.42), those infected with bacteria having the A2143G mutation demonstrated a lower H. pylori eradication rate compared with patients infected with either wild-type (RD=0.72 [0.64–0.80]; I2=0%; p<0.001) or A2143G mutant bacteria (RD=0.76 [0.61–0.91]; I2=0%; p< 0.001). Conclusions: The A2143G mutation may play a more significant role in clarithromycin triple therapy H. pylori eradication failure than does the A2142G mutation. Additionally, H. pylori strains with the A2142G mutation can be treated effectively with clarithromycin-based triple therapy.
- 10 December 2023
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 23 (4) , 268-276
Open AccessTypes of 23S Ribosomal RNA Point Mutations Affecting Helicobacter pylori Eradication Rates in Clarithromycin-Based Triple Therapy
Objectives: The A2142G and A2143G mutations in the 23S ribosomal ribonucleic acid (rRNA) of Helicobacter pylori are the most common mutations associated with clarithromycin resistance. This study aimed to determine the differences in H. pylori eradication rates in patients infected with bacteria carrying the A2142G and A2143G mutations who were treated with clarithromycin-based triple therapy. Methods: Data from a previous randomized controlled trial were analyzed retrospectively. Eradication rates were compared based on the presence of H. pylori carrying the A2142G and A2143G mutations. A meta-analysis was also conducted of relevant studies containing data regarding patients who received clarithromycin-based therapy due to infections with H. pylori harboring 23S rRNA mutations. Results: No significant difference was observed in H. pylori eradication rates between patients infected with wild-type bacteria (95.7% [44/46]) compared with those infected with bacteria carrying the A2142G mutation (100.0% [3/3]; p>0.9). However, the eradication rate was significantly lower for patients infected with bacteria carrying the A2143G mutation (16.7% [1/6]; p<0.001) than for those infected with wild-type bacteria or bacteria with the A2142G mutation (100.0% [3/3]; p=0.048). In the meta-analysis, the between-group comparisons yielded similar results. Although patients infected with bacteria having the A2142G mutation exhibited no significant risk difference (RD) for eradication compared with those infected with wild-type bacteria (RD=-0.05 [-0.18 to 0.08]; I2=0%; p=0.42), those infected with bacteria having the A2143G mutation demonstrated a lower H. pylori eradication rate compared with patients infected with either wild-type (RD=0.72 [0.64–0.80]; I2=0%; p<0.001) or A2143G mutant bacteria (RD=0.76 [0.61–0.91]; I2=0%; p< 0.001). Conclusions: The A2143G mutation may play a more significant role in clarithromycin triple therapy H. pylori eradication failure than does the A2142G mutation. Additionally, H. pylori strains with the A2142G mutation can be treated effectively with clarithromycin-based triple therapy.